| Literature DB >> 25243195 |
M R Lopes1, Paula A B Ribeiro2, Priscila Ledur1, Gabriela C Souza3, Nadine Clausell4, Beatriz D Schaan5.
Abstract
Vitamin D deficiency is frequent among patients with heart failure (HF) and diabetes, disorders associated with exercise intolerance and muscle weakness. This study aims to search for associations between vitamin D sufficiency and physical function indexes in patients with HF and diabetes. A cross-sectional study of 146 HF patients, 39.7% with diabetes, at a Brazilian tertiary outpatient clinic was performed. Patients underwent clinical evaluation, 6-minute walk test (6 MWT), handgrip strength, physical activity level (IPAQ), and biochemical evaluations including serum 25-hydroxyvitamin D. Classification was done according to vitamin D status (≥ 30 ng/dL, sufficient) and presence/absence of diabetes in vitamin sufficient, no diabetes (DS-C, n = 25), vitamin sufficient, diabetes (DS-DM, n = 18), vitamin deficient, no diabetes (DD-C, n = 63), and vitamin deficient, diabetes (DD-DM, n = 40). Patients age was 55.4 ± 8 yrs; 70.5% had vitamin D deficiency. Clinical characteristics were similar among groups. Total time expended in physical activity was similar among groups (P = 0.26). DS-C covered higher distances in the 6 MWT (392 ± 60 m) versus DD-DM (309 ± 116 m); P = 0.024. Handgrip strength was similar among groups but tended to lower levels in DD-DM (P = 0.074) even after being adjusted to physical activity (P = 0.069). Vitamin D deficiency can influence physical function in HF diabetic patients.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25243195 PMCID: PMC4158566 DOI: 10.1155/2014/320930
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Clinical and biochemical characteristics according to vitamin D status and diabetes mellitus.
| Characteristc | Vitamin D sufficient | Vitamin D insufficient |
| ||
|---|---|---|---|---|---|
| ( | ( | ||||
| No DM | DM | No DM | DM | ||
|
|
|
|
| ||
| Male | 17 (68.0) | 13 (72.2) | 39 (61.9) | 26 (65.0) | 0.855 |
| Age (years) | 54.4 ± 9 | 57.8 ± 6 | 53.1 ± 9 | 56.2 ± 6 | 0.051 |
| Caucasian | 19 (76.0) | 17 (94.4) | 49 (77.8) | 32 (82.1) | 0.106 |
| Previous cardiovascular disease∗ | 9 (36) | 7 (38.9) | 38 (60.3) | 25 (62.5) | 0.050 |
| LVEF (%) | 39.1 ± 16 | 36.7 ± 11.9 | 31.5 ± 13.3 | 35.5 ± 14 | 0.101 |
| Left ventricular dysfunction | 18 (72) | 14 (78) | 55 (87) | 28 (70) | 0.166 |
| Functional Class (NYHA) | |||||
| I | 11 (47.8) | 8 (57.1) | 22 (36.7) | 10 (33.3) | 0.424 |
| II | 8 (34.8) | 5 (35.7) | 27 (45.0) | 9 (30.0) | |
| III | 4 (17.4) | 1 (7.1) | 9 (15.0) | 9 (30.0) | |
| IV | 0 (0.0) | 0 (0.0) | 2 (3.3) | 2 (6.7) | |
| Drugs in use | |||||
| Metformin | — | 12 (66.7) | — | 23 (57.5) | <0.001 |
| Sulfonyurea | — | 5 (27.8) | — | 9 (22.5) | <0.001 |
| Insulin | — | 4 (22.2) | — | 12 (30.0) | <0.001 |
| Diuretic | 18 (72.0) | 15 (83.3) | 55 (87.3) | 37 (92.5) | 0.137 |
| ACEi or ARA II | 22 (88.0) | 14 (77.8) | 51 (81.0) | 31 (77.5) | 0.747 |
| Aspirin | 7 (28.0) | 13 (72.2) | 30 (47.6) | 26 (65.0) | 0.008 |
| Mass (Kg) | 82.1 ± 17 | 81.9 ± 13 | 75.3 ± 16 | 84.6 ± 20 | 0.992 |
| BMI (Kg/m2) | 28.7AB ± 5 | 30.2AB ± 5 | 27.7A ± 5 | 31.5B ± 6 | 0.007 |
| Muscle mass (kg) | 31.9 ± 7 | 30.4 ± 5 | 28.7 ± 7 | 32.1 ± 10 | 0.163 |
| Fat mass (Kg) | 25.4 ± 9 | 27.5 ± 10 | 24.2 ± 9 | 27.7 ± 12 | 0.339 |
| Metabolic basal rate (Kilocalories) | 1597 ± 265 | 1461 ± 400 | 1475 ± 248 | 1607 ± 342 | 0.078 |
| Waist circumference (cm) | 100.4AB ± 11 | 105AB ± 20 | 99.0A ± 14 | 107.1B ± 15 | 0.031 |
| Arm circumference (cm) | 33.2 ± 5 | 34.6 ± 4 | 32.3 ± 5 | 33.9 ± 4 | 0.154 |
| Tricipital fold (mm) | 18.6 ± 7 | 22.2 ± 9 | 20.0 ± 8 | 21.9 ± 9 | 0.375 |
| Systolic arterial pressure (mmHg) | 122.2 ± 22 | 115.9 ± 14 | 121.8 ± 23 | 130.4 ± 18.7 | 0.077 |
| Diastolic arterial pressure (mmHg) | 78.8 ± 12 | 76.6 ± 11 | 80.8 ± 19 | 81.9 ± 15 | 0.479 |
| HbA1c (% and mmol/mol) | — | 8.3 ± 3 | — | 7.7 ± 2 | 0.442 |
| (67 ± 2) | (61 ± 2) | ||||
| Total cholesterol (mg/dL) | 188.5 ± 41 | 161.0 ± 28 | 178.8 ± 47 | 179.5 ± 69 | 0.440 |
| HDL cholesterol (mg/dL) | 41.7 ± 12 | 37.7 ± 9 | 38.1 ± 10 | 37.1 ± 8 | 0.382 |
| Triglycerides (mg/dL) | 149 (100–202) | 163 (105–196) | 153 (114–214) | 138 (99–273) | 0.524 |
| Prothrombin time (s) | 16.0 ± 8 | 15.3 ± 7 | 15.3 ± 7 | 16.0 ± 8 | 0.957 |
| Calcium (mg/dL)∗∗ | 9.3 ± 1 | 9.3 ± 1 | 9.4 ± 1 | 9.5 ± 1 | 0.662 |
| Magnesium (mg/dL) | 2.1 ± 0 | 1.9 ± 0 | 2.1 ± 0 | 2.0 ± 0 | 0.060 |
| PTH (pg/mL) | 63.6 ± 20 | 62.7 ± 34 | 77.6 ± 38 | 78.3 ± 42 | 0.186 |
| Hemoglobin (g/dL) | 14.2B ± 1 | 13.3AB ± 2 | 13.7AB ± 2 | 12.8A ± 2 | 0.007 |
| GFR (mL/min/m2)∗∗∗ | 95.4 ± 37 | 88.0 ± 35 | 86.7 ± 27 | 90.9 ± 40 | 0.739 |
| CRP (mg/dL) | 3.8 (1.7–6.9) | 5.3 (2.1–8.8) | 2.9 (1.1–6.7) | 3.5 (1.0–10.6) | 0.383 |
Mean ± standard deviation, n (%) or median (P25–P75), as needed. Different letters indicate statistically significant differences between groups (ANOVA with Tukey post-hoc). DM: diabetes mellitus; LVEF: left vetricular ejection fraction; GFR: glomerular fraction rate. ACEi: angiotensin converting enzyme inhibitors. ARA II: angiotensin II receptor blockers. Mass, body mass index (BMI), muscle mass, fat mass and basal metabolic rate were obtained using bioimpedanciometry. HbA1c (glycated hemoglobin), is expressed in NGSP units (%) and in IFCC units (mmol/mol). PTH: parathyroid hormone. ∗Previous cardiovascular disease included myocardial infarction, coronary artery bypass graft surgery and percutaneous coronary revascularization. ∗∗Corrected for albumin. ∗∗∗GFR was calculated with the MDRD equation.
Food intake and caloric consumption according to vitamin D and diabetes mellitus.
| Characteristic | Vitamin D sufficient | Vitamin D insufficient |
| ||
|---|---|---|---|---|---|
| ( | ( | ||||
| No DM | DM | No DM | DM | ||
|
|
|
|
| ||
| Total caloric intake (Kcal) | 1702AB (1210–2461) | 1455AB (1250–1881) | 1483B (1133–2117) | 1312A (989–1572) | 0.032 |
| Carbohydrates (%) | 48.3 (42–57) | 50.7 (48–54) | 55.3 (46–63) | 56.5 (48–62) | 0.158 |
| Proteins (%) | 17.9 (14–24) | 16.8 (15–21) | 18.4 (15–21) | 19.5 (16–22) | 0.603 |
| Fat (%) | 31.2 (25–48) | 31.4 (28–35) | 30.7 (22–39) | 25.4 (20–37) | 0.066 |
| Calcium (mg/dL) | 539 (285–679) | 583 (289–741) | 434 (237–688) | 474 (286–760) | 0.860 |
| Vitamin D (mcg) | 1.9 (1–3) | 3.6 (2–7) | 2.0 (0–4) | 2.1 (1–4) | 0.250 |
Median (P25–P75), as needed. Different letters indicate statistically significant differences between groups (Kruskall-Wallis). DM: diabetes mellitus.
Figure 1Physical activity (PA) expressed through the domains obtained from the IPAQ for the groups studied (no vitamin deficiency and no diabetes, DS-C; no vitamin deficiency and diabetes, DS-DM; vitamin deficiency and no diabetes, DD-C; and vitamin deficiency and diabetes, DD-DM).
Six minutes walking test-submaximal physical function according to vitamin D and diabetes mellitus.
| Characteristic | Vitamin D sufficient | Vitamin D insufficient |
| ||
|---|---|---|---|---|---|
| ( | ( | ||||
| No DM | DM | No DM | DM | ||
|
|
|
|
| ||
| Distance covered (m) | 398 (354–437) | 344 (330–461) | 375 (320–440) | 325 (271–371)∗ | 0.014 |
| ≥300 m | 24 (96.0) | 14 (82.4) | 51 (81.0) | 26 (65.0)∗ | 0.024 |
| Final HR (bpm) | 101.6 ± 24 | 94.2 ± 32 | 97.6 ± 24 | 99.7 ± 32 | 0.835 |
| Recovery HR (bpm) | 86.4 ± 21 | 85.6 ± 18 | 82.8 ± 22 | 86.1 ± 20 | 0.825 |
| Referred a high rate of perceived exertion# | 16 (64.0) | 14 (82.4) | 39 (62.9) | 21 (52.5) | 0.204 |
Mean ± standard-deviation, n (%), or median (P25–P75), as needed. ANOVA and chi-square statistics. ∗Different from No DM, vitamin sufficient. DM: diabetes mellitus; HR: heart rate.
#Rate of perceived exertion was measured with the Borg Scale (6–20).
Cardiopulmonary exercise test-metabolic and ventilatory characteristics according to vitamin D and diabetes mellitus.
| Characteristic | Vitamin D sufficient | Vitamin D insufficient |
| ||
|---|---|---|---|---|---|
| ( | ( | ||||
| No DM | DM | No DM | DM | ||
|
|
|
|
| ||
| VO2 peak (mL/kg/min) | 20.0 ± 5 | 15.6 ± 3 | 18 ± 5 | 19.2 ± 5 | 0.134 |
| ≤14 mL mL/kg/min | 1 (7.1) | 3 (33.3) | 8 (21.1) | 2 (9.1) | |
| >14 mL mL/kg/min | 13 (92.9) | 6 (66.7) | 30 (78.9) | 20 (90.9) | 0.250 |
| VE/VCO2slope | 35.8 ± 11 | 41.5 ± 5 | 37.3 ± 11 | 36.7 ± 9 | 0.636 |
| >34 | 6 (42.9) | 8 (100.0) | 22 (62.9) | 13 (65.0) | |
| ≤34 | 8 (57.1) | 0 (0.0) | 13 (37.1) | 7 (35.0) | 0.066 |
| Weber Class | |||||
| I | 5 (35.7) | 2 (22.2) | 13 (34.2) | 8 (36.4) | |
| II | 8 (57.1) | 1 (11.1) | 16 (42.1) | 9 (40.9) | |
| III | 1 (7.1) | 6 (66.7) | 7 (18.4) | 3 (13.6) | |
| IV | 0 (0.0) | 0 (0.0) | 2 (5.3) | 2 (9.1) | 0.059 |
| HR peak (bpm) | 139.8 ± 31 | 141.9 ± 27 | 137.4 ± 24 | 134.9 ± 28 | 0.909 |
| Systolic arterial pressure (mmHg) | 146 ± 35 | 140.4 ± 22 | 137.1 ± 32 | 148.7 ± 25 | 0.516 |
| Diastolic arterial pressure (mmHg) | 74.5 ± 16 | 73.5 ± 9 | 71.6 ± 15 | 74.1 ± 14 | 0.893 |
| O2 pulse (mL | 11.61 ± 4 | 9.2 ± 2 | 10.9 ± 4 | 19.0 ± 30 | 0.236 |
Mean ± standard deviation, or n (%), as needed. ANOVA and Chi-square statistics. DM: diabetes mellitus. VO2 peak: peak oxigen consumption. Weber class: I: >20; II: 16–20; III: 10–16; IV: <10.